AGT and cardiac hypertrophy: Intriguingly, exogenous NAD+ seems to be of equal significance; daily NAD+ treatment maintained intracellular levels of NAD+ and prevented phenylephrine-induced in vitro hypertrophy in cultured cardiomyocytes and angiotensin II-induced cardiac hypertrophy in vivo in mice (Pillai et al., 2010).